

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

HCC70

RRID:CVCL_1270

Type: Cell Line

Proper Citation

RRID:CVCL_1270

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1270

Proper Citation: RRID:CVCL_1270

Description: Cell line HCC70 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:17157791](#), [PMID:18516279](#), [PMID:19582160](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:29473000](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: African American., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC70

Synonyms: HCC-70, HCC 70, HCC0070, Hamon Cancer Center 70

Cross References: BTO:BTO_0005963, CLO:CLO_0003658, EFO:EFO_0001181, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:CRL-2315, BCRJ:0386, BioGRID_ORCS_Cell_line:870, BioSample:SAMN03471365, BioSample:SAMN03471868, BioSample:SAMN10988137, cancercellines:CVCL_1270, Cell_Model_Passport:SIDM00673, ChEMBL-Cells:ChEMBL3308739, ChEMBL-Targets:ChEMBL1075461, CLS:305464, Cosmic:687486, Cosmic:904357, Cosmic:907048, Cosmic:1018474, Cosmic:1047703, Cosmic:1136352, Cosmic:1287933, Cosmic:1603213, Cosmic:1935001, Cosmic:1995435, Cosmic:2164994, Cosmic-CLP:907048, DepMap:ACH-000668, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:907048, GEO:GSM217580, GEO:GSM344372, GEO:GSM344422, GEO:GSM350500, GEO:GSM718288, GEO:GSM783941, GEO:GSM844014, GEO:GSM844015, GEO:GSM847391, GEO:GSM887058, GEO:GSM888128, GEO:GSM1053711, GEO:GSM1172876, GEO:GSM1172969, GEO:GSM1374512, GEO:GSM1401660, GEO:GSM1669862, IARC_TP53:10269, IGRhCellID:HCC70, KCLB:9S0070, LiGeA:CCL_774, LINCS_HMS:50219, LINCS_LDP:LCL-1335, PharmacDB:HCC70_509_2019, PRIDE:PXD005295, PRIDE:PXD030304, Progenetix:CVCL_1270, PubChem_Cell_line:CVCL_1270, SLKBase:3492, Wikidata:Q54881772

ID: CVCL_1270

Record Creation Time: 20220427T220319+0000

Record Last Update: 20260920T003520+0000

Ratings and Alerts

No rating or validation information has been found for HCC70.

No alerts have been found for HCC70.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 375 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Tang S, et al. (2026) PTEN Loss Promotes PI3K? Phosphorylation and EPHA2/SRC/p-PI3K?Y962 Complex Assembly to Drive Tumorigenesis. Cancer discovery, 16(3), 521.

Ortega-Álvarez D, et al. (2026) Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies. Cancer research, 86(10), 2360.

Koul S, et al. (2026) Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells. *Molecular cancer research : MCR*.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Zhu XR, et al. (2026) PFDN5 synergizes with anti-PD1 therapy to promote triple-negative breast cancer cell death through JAK2/STAT3/c-Myc signaling axis. *Journal of translational medicine*, 24(1).

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. *Cell chemical biology*.

Nagahashi M, et al. (2025) An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. *Cancer research communications*, 5(6), 981.

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. *Cancer research communications*, 5(3), 458.

Zhang Y, et al. (2025) Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform. *Cell reports. Medicine*, 6(7), 102198.

N'Guessan É, et al. (2025) Comparative theranostic efficacy of ¹⁷⁷Lu- and ¹⁶¹Tb-labeled A1K2 SdAb in mesothelin-positive tumors. *European journal of nuclear medicine and molecular imaging*.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Jeon JH, et al. (2025) Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer. *Cancer & metabolism*, 13(1), 42.

Mahajan M, et al. (2025) The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer. *Molecular cancer therapeutics*, 24(9), 1308.

Koul S, et al. (2025) Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells. *bioRxiv : the preprint server for biology*.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. *Cancer research communications*, 5(2), 375.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. *Frontiers in oncology*, 15, 1549282.

Rosenbaum SR, et al. (2025) EYA3 regulation of NF- κ B and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis. *Science advances*, 11(19), eadt0504.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1275.

Minati R, et al. (2025) CDK4/6 inhibition reprograms the breast cancer immunopeptidome via Rb-dependent chromatin and transcriptomic remodeling. *Cell reports*, 44(12), 116676.

Papacharisi E, et al. (2024) Novel Amanitin-based Antibody Drug Conjugates (ATAC®) targeting TROP2 for the treatment of Pancreatic Cancer. *Molecular cancer therapeutics*.